Matt Wall (@mattwall.bsky.social)

Psychologist & fMRI-nerd @Invicro & @ImperialMed. 🧠 + psychedelics, cannabis, sex hormones. Instrument botherer. The secret is to bang the rocks together, guys

[Matt Wall (@mattwall.bsky.social) @m_wall]

*Ahem* What I did on my lockdown (part 1). I taught myself the basics of audio production, & recorded a silly song about my favourite imaging modality. I humbly present "The MRI song" in the hope it's a brief distraction from the general hideousness.
https://t.co/aVEpiT6kw2

[Matt Wall (@mattwall.bsky.social) @m_wall]

Haven't done one of these for quite a while, but I regret to inform you that I've hideously butchered another classic song in the name of making some weak jokes.
I present: Psychedelic Therapy: The song.
Have a great time at #PS2025 everyone!
https://t.co/PYCSuuZTxK

[Robin Carhart-Harris @RCarhartHarris]

Grateful to @m_wall: Human [psychedelic] neuroimaging: fMRI https://t.co/wqq4bON7eP

[Matt Wall (@mattwall.bsky.social) @m_wall]

@RCarhartHarris Oh, it's out! Nice. 👍

[Joshua Siegel @realJoshSiegel]

This extraordinary psychedelic precision functional mapping dataset is now fully/freely available to all!

All the info to access & use it in a newly published Nature Scientific Data Resource: https://t.co/W6lRzv7u2b

Thanks to the incredible team who created it - Subha S, Rick R, Ginger N, Demetrius P, Nick M, to name a few.

[Robin Carhart-Harris @RCarhartHarris]

Very nice work here...

[Leor Roseman 🦋 @leorroseman.bsky.social @LeorRoseman]

New in @NatureMedicine: ReSPCT "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by @ChloePronovostM, Kyle Greenway, myself, and many ReSPCT Experts. "The ReSPCT guidelines and accompanying explanatory document provide a new standard for the design and documentation of extra-pharmacological variables in psychedelic clinical research."
https://t.co/wNnggwG0z9

https://t.co/7YeQXsbsTe

[Manoj Doss not exist @ManojDoss]

Our (@GregFonzo and Charlie Nemeroff) commentary on @m_wall's recent paper comparing effects of psilocybin and escitalopram on emotional responses in the brain.
https://t.co/GPk0sGm1xt

[Matt Wall (@mattwall.bsky.social) @m_wall]

RT @PeterSjostedtH: Very sad to hear that Lady Amanda Feilding has passed. Without her much twenty-first century research on psychədəlics w…

[George Chapman @Chapman_GE]

🚨New paper day! 🚨

Led by the super @pSelvaggi, we found that one week of (barely) treatment dose amisulpride or aripiprazole led to reversible increases in striatal volumes on MRI in healthy volunteers 👇

Why does this matter?? … …

[内田裕之 (Hiroyuki Uchida) @Uchida_Keio_Psy]

Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan ｜News Releases | Otsuka Pharmaceutical Co., Ltd. https://t.co/TaXxiQKZ8t

[Matt Wall (@mattwall.bsky.social) @m_wall]

@RCarhartHarris Thanks Robin! 😀

[Robin Carhart-Harris @RCarhartHarris]

This is a big one. Classic work by @m_wall and co! Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression https://t.co/YM3Rpx4Z6M

[Balázs Szigeti @psybalazs]

🚨New paper alarm🚨
Excited to share our new publication that breaks new grounds for #psychedelic medicine: the first data on #psilocybin’s effects in any neurodegenerative disease, specifically psilocybin for the treatment of #Parkinson's disease!

It was a phase 1 feasibility and tolerability study on 12 patients with all the usual limitations of such studies, e.g. lack of control condition. The treatment consisted of 2 psilocybin sessions, the first with 10mg and then a larger 25mg dose 2 weeks later. As usual psilocybin was coupled with therapy.

The study's primary objective was to treat the mood dysfunction associated with Parkinson's. We got the usual large and positive treatment effects as other psilocybin trials: three months after the last dose MADRS significantly improved by 9.3 points, corresponding to 1.0 standardized mean difference (SMD; i.e. large effect). Anxiety, as captured by the Hamilton Anxiety Rating Scale, also significantly improved by 3.8 points, corresponding to 0.7 SMD.

More surprisingly, Parkinson's symptoms also improved post-psilocybin! We captured Parkinson's with the standard MDS-UPDRS assessment, , and patients significantly improved in all domains at every post-treatment timepoint (!!!) with mostly moderate-to-large effect sizes. Benefits persisted at the 3 months post last dose timepoint.

No serious adverse events (AEs) occurred. As expected, most AEs occurred during psilocybin sessions (anxiety, nausea, headache) and were self-resolving and transient.

Even better than the paper that we are already running the follow-up phase 2 trial! If you know anyone in the Bay area who could be interested, please let them know: https://t.co/BCVdPT9Ytx.

Full paper: https://t.co/9ujh4qAgpq

Celebrating with @EllenBradleyMD, @thebandlab and the whole @UCSF's @TrPR_Program crew! 🙏🫂❤️

[Jakub Schimmelpfennig @psychedmt]

Neuroscience shows neural oscillations sync with music via neural resonance theory. Not just prediction—brain-body dynamics embody musical structure, driving perception. This may amplify psychedelic experiences, resonating with ASC.

https://t.co/XmzFW5U2tG

[Michel Thiebaut de S @MichelTdS]

🧠 Just out in Nature: A human brain map of mitochondrial diversity. A powerful collaboration with Mosharov and @MitoPsychoBio. Big step toward bridging cell biology and neuroimaging!
🔗 https://t.co/4X7PVKFsaU
🧬 #MitoBrainMap #neuroscience

[Brian Edlow @ComaRecoveryLab]

Visualizing Effective Connectivity in the Human Brain

Preprint: https://t.co/ZiORqUJmHs
Code: https://t.co/lKtRg6pCsT
YouTube video: https://t.co/ISwd5ahs7M
Download video & figures: https://t.co/PVlPXDoAVY

Led by #XanderAtalay & #TeoFecchio

@MGH_CNTR @MGHMartinos @MGHNeuroICU

[Matt Wall (@mattwall.bsky.social) @m_wall]

@neurodelia @lisaxiaolu @Imperial_PRG Amazing! Congratulations Lisa!

[Micah G. Allen @micahgallen]

Beyond happy to share this study with you - Ashley and the team have really exceeded all expectations. Computational modelling of drug effects on multi-domain interoception!

[Rob_McCutcheon @rob_mccutcheon]

New paper with @Matt_Nour , @tobypill , and Phil Cowen discussing different ways of thinking about and developing psychopharmacological treatments https://t.co/qnMYwSZu7m

[Marina Hyde @MarinaHyde]

My column on Donald Trump’s “peace plan” for Ukraine

https://t.co/Z5TCR4g3CC